Evidence map›Paper›PMID 30814267›Full record

ArticleJournal of clinical microbiology2019

Development of the TypeSeq Assay for Detection of 51 Human Papillomavirus Genotypes by Next-Generation Sequencing.

Sarah Wagner, David Roberson, Joseph Boland, Meredith Yeager, Michael Cullen, Lisa Mirabello, S Terence Dunn, Joan Walker, Rosemary Zuna, Mark Schiffman and 1 more

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Decreases in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers: HPV-IMPACT, 2008 to 2019.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A human papillomavirus whole genome plasmid repository: A resource for HPV DNA quality control reagents.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah WagnerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA wagnersa@mail.nih.gov wentzenn@mail.nih.gov.ORCID 0000-0002-0223-2388
David RobersonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Joseph BolandDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Meredith YeagerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Michael CullenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Lisa MirabelloDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
S Terence DunnUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Joan WalkerUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Rosemary ZunaUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA wagnersa@mail.nih.gov wentzenn@mail.nih.gov.

Funding

A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUG1CA233193 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Muhammad Furqan · 2019 to 2026
$13.7M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS UG1 CA233193
6 · The paper itself

Abstract

We have developed a new human papillomavirus (HPV) genotyping assay for detection of 51 HPV genotypes by next-generation sequencing (NGS). The TypeSeq assay consists of 3 PCR steps that equalize viral load and each type's amplicon copies prior to genotyping by NGS, thereby maximizing multiple-type sensitivity with minimal sequencing reads. The analytical sensitivity of the TypeSeq assay is 10 copies per reaction for 49 of the 51 types, including 13 high-risk (HR) types. We tested 863 clinical cervical specimens previously evaluated with the Roche Linear Array HPV genotyping test (LA). TypeSeq achieved 94.4% positive agreement with LA for detection of any HR type. Positive agreement was 91.4% and 85.5% for HPV16 and HPV18, respectively. Low-risk (LR) types ranged from 40.0% positive agreement (HPV83) to 90.9% (HPV69). Our unique approach to HPV amplification achieved a multiple-type sensitivity comparable to that of LA, with 83.9% and 84.2% of specimens positive for multiple HPV types by TypeSeq or LA, respectively. A total of 48.2% of specimens showed perfect agreement for all 37 types common to both assays. The simplicity of our open-source TypeSeq assay allows for high-throughput yet scalable processing, with a single technician able to process up to 768 specimens within 3 days. By leveraging NGS sample multiplexing capabilities, the per-sample labor requirements are greatly reduced compared to those of traditional genotyping methods. These features and the broad spectrum of detectable types make TypeSeq highly suitable for a wide range of applications.

Indexed as

High-Throughput Nucleotide SequencingCervix UteriDNA, ViralFemaleGenotypeGenotyping TechniquesHuman papillomavirus 16Human papillomavirus 18HumansNucleic Acid Amplification TechniquesPapillomaviridaePapillomavirus InfectionsSensitivity and SpecificitySequence Analysis, DNAUterine Cervical NeoplasmsViral LoadDNA, Viralcervical cancerHPVHPV genotypingSUCCEED

Identifiers

PMID30814267
PMCPMC6498001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.